Cargando…
Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
The disease burden related to hepatocellular carcinoma (HCC) is increasing. Most HCC patients are diagnosed at the advanced stage and multikinase inhibitors have been the only treatment choice for them. Recently, the approval of immune checkpoint inhibitors (ICIs) has provided a new therapeutic stra...
Autores principales: | Li, Si-Qi, Yang, Yang, Ye, Lin-Sen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669824/ https://www.ncbi.nlm.nih.gov/pubmed/36405383 http://dx.doi.org/10.3748/wjg.v28.i42.6034 |
Ejemplares similares
-
Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma
por: Lee, Byung Min, et al.
Publicado: (2021) -
Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017) -
Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges
por: Zhu, Lingling, et al.
Publicado: (2021) -
Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
por: Zhang, Qi, et al.
Publicado: (2020) -
Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges
por: Wang, Di, et al.
Publicado: (2023)